Villejuif, France, October 26, 2022 at 6:30 p.m. CET – PREDILIFE
(Euronext Growth: ALPRE FR0010169920), a specialist in innovative disease risk prediction solutions for personalized medicine, today announces its 2022 half-year results approved by the Board of Directors on October 21, 2022 and subject to a limited review by the auditor.
Stéphane Ragusa, Chairman and Chief Executive Officer of the Company declares:
half of 2022 was marked by the growth in sales of MammoRisk tests to hospitals but above all by the acceleration in sales of the predictive assessments to companies launched in the fall of 2021. Since the start of the year, we have multiplied the signatures with companies adopting this solution for their employees, in sectors as varied as finance, agri-food, IT or distribution. This diversity of client companies demonstrates the breadth of the market and reinforces Predilife’s confidence in the upward pursuit of its activity in the second half of 2022.”
Selected financial information as of June 30, 2022
Other exploitation products
Cash and cash equivalents at closing
During the 1
semester 2022, the Group achieved a turnover of €151,476 compared to €39,216 in 2021, an increase of 286%. A third comes from the sale of MammoRisk tests to doctors and hospitals and two thirds to companies, first and foremost Allianz and Nuoma Mutuelle.
This increase in expenses was concomitant with a drop in expenses, the two combined effects enabling a reduction in the half-year loss.
Cash at June 30, 2022 was increased on July 11 by €1.75m after the OCEANE issue launched in June 2022, i.e. a total of €3.2m.
PREDILIFE will continue on 2
half of 2022 its commercialization strategy with companies by opening up to new sectors of activity including luxury, media, construction and catering. Growth in the second half should be confirmed thanks to a diversified client portfolio.
The 2022 half-year financial report will be published no later than October 31, 2022.
PREDILIFE Investor Relations
Chairman and CEO
CAPVALUE Press Relations
PREDILIFE is a pioneering company in the design and development of predictive tests that can allow each person to define their risk profile for the occurrence of serious illnesses. It uses artificial intelligence methods applied to clinical and genetic medical data in a secure legal framework. The prediction of these individual risks makes it possible to propose a personalized monitoring protocol and earlier identification of pathologies. PREDILIFE markets in Europe Mammorisk®, a breast cancer risk prediction test.
For more information: www.predilife.com
This release contains non-factual materials, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current view and assumptions of the Company’s management. They incorporate known and unknown risks and uncertainties that could cause actual results, profitability and expected events to differ materially. In addition, Predilife, its shareholders and its respective affiliates, directors, officers, councils and employees have not verified the accuracy of, and make no representations or warranties about, the statistical information or the forward-looking information contained in this press release. which are or are derived from third party sources or industry publications. These statistical data and forward-looking information are used in this press release for informational purposes only.
This post has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
– To check this key:
– Press release on accounts, results
Full and original press release in PDF format:
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com